

## Medical drug benefit Clinical Criteria updates

On February 21, 2020, May 15, 2020, and June 18, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Amerigroup Washington, Inc. These policies were developed, revised or reviewed to support clinical coding edits.

Visit *Clinical Criteria* to search for specific policies. If you have questions or would like additional information, use this **email**.

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (\*): criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical plan. This does not apply to pharmacy services.

Effective date	Document number	Clinical Criteria title	New, revised,
			annual review
11/18/2020	ING-CC-0164*	Jelmyto (mitomycin gel)	New
11/18/2020	ING-CC-0165*	Trodelvy (sacituzumab govitecan)	New
11/18/2020	ING-CC-0029	Dupixent (dupilumab)	Revised
11/18/2020	ING-CC-0107	Bevacizumab for	Revised
	ING-CC-0107	Non-Ophthalmologic Indications	
11/18/2020		Darzalex (daratumumab) and	
	ING-CC-0127*	Darzalex Faspro (daratumumab and	Revised
		hyaluronidase-fihj)	
11/18/2020	ING-CC-0128	Tecentriq (atezolizumab)	Revised
11/18/2020	ING-CC-0125	Opdivo (nivolumab)	Revised
11/18/2020	ING-CC-0119	Yervoy (ipilimumab)	Revised
11/18/2020	ING-CC-0051*	Enzyme Replacement Therapy for	Revised
		Gaucher Disease	
11/18/2020	ING-CC-0061*	GnRH Analogs for the Treatment of	Revised
		Non-Oncologic Indications	
11/18/2020	ING-CC-0042	Monoclonal Antibodies to	Revised
		Interleukin-17	
11/18/2020	ING-CC-0011*	Ocrevus (ocrelizumab)	Revised

Effective date	Document number	Clinical Criteria title	New, revised, annual review
11/18/2020	ING-CC-0002*	Colony Stimulating Factor Agents	Revised